Physician profile

Thomas Herrick

Urology · North Kansas City, MO

NPI 1487605275

$6,194.18

in general payments reported to CMS, 2019-2025

44 companies · $609 in 2025

The $609 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).

See the full distribution for Urology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,708.66
Education$338.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Teleflex LLC $1,067.29 2021-2025 Urolift
Astellas Pharma US INC $1,028.79 2019-2025 Xtandi, Myrbetriq
Janssen Biotech, INC. $572.36 2019-2024 Erleada
Procept Biorobotics Corporation $462.05 2022-2025 Aquabeam Robotic System, Aquabeam System
Abbvie INC. $336.44 2020-2025
Mevion_medical_systems_inc $308.69 2021
Novartis Pharmaceuticals Corporation $284.19 2022-2025
Dendreon Pharmaceuticals LLC $245.33 2019-2021
Antares Pharma, INC. $181.88 2019-2025 Xyosted, Tlando, Nocdurna
Pfizer INC. $179.59 2019-2024
Karl Storz Endoscopy-America $145.73 2019-2023 Flex-X
Olympus America INC. $139.58 2019-2025 Itind System
Blue Earth Diagnostics $115.16 2019-2023
Boston Scientific Corporation $100.31 2019-2024 Spaceoar Vue System - 10ml
Merck Sharp & Dohme LLC $91.19 2023-2025 Keytruda, Lynparza
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Sumitomo Pharma America, INC. $85.56 2023-2025 Gemtesa, Orgovyx
Allergan, INC. $74.33 2019-2021
Photocure INC $62.98 2019
180 Medical, INC. $52.33 2021-2023 Speedicath
Amgen INC. $50.60 2019-2021
Endo Pharmaceuticals INC. $48.74 2021-2023 Xiaflex
Urovant Sciences INC $45.89 2021-2022
Valencia Technologies Corporation $45.34 2022
Bayer Healthcare Pharmaceuticals INC. $42.25 2021-2022
Travere Therapeutics, INC. $41.30 2019
Cycle Pharmaceuticals INC $38.86 2025 Venxxiva
Urogen Pharma, INC. $36.41 2021-2025
Biotissue Holdings INC. $34.93 2023
Tolmar, INC. $26.15 2023
C. R. Bard, INC. & Subsidiaries $23.69 2019
Progenics Pharmaceuticals, INC. $23.02 2023 Pylarify
Calyxo, INC. $19.79 2025 Cvac Aspiration System
Astrazeneca Pharmaceuticals LP $19.20 2025 Lynparza
Ferring Pharmaceuticals INC. $17.27 2019
Coloplast Corp $17.01 2023 Speedicath
Avadel Specialty Pharmaceuticals, LLC $16.26 2019
Halozyme INC $15.90 2023
Medtronic, INC. $14.85 2021
Axonics, INC. $14.73 2022
Verity Pharmaceuticals INC. $14.44 2025 Trelstar
Alnylam Pharmaceuticals INC. $14.33 2021
Myovant Sciences INC. $14.10 2021
Rochester Medical Corporation $12.90 2019
Myriad Genetic Laboratories, INC. $12.44 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Herrick

$6,194.18

in general payments reported 2019-2025

Years
2019-2025
Top company
Teleflex LLC
Context
The $609 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/339184/thomas-herrick

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.